Mirtazapine CAS 85650-52-8
Introduction：Basic information about Mirtazapine CAS 85650-52-8, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Mirtazapine Basic information
| Product Name: | Mirtazapine |
| Synonyms: | 1,2,3,4,10,14B-HEXAHYDRO-2-METHYLPYRAZINO[2,1-A]PYRIDO[2,3-C][2]BENZAZEPINE;(rs)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino-[2,1-a]pyrido[2,3-c][2]benzazepine;REMERON;ORG-3770;MIRTAZANINE;MIRTAZAPINE;MIRTAZEPINE;ZISPIN |
| CAS: | 85650-52-8 |
| MF: | C17H19N3 |
| MW: | 265.35 |
| EINECS: | 288-060-6 |
| Product Categories: | Other APIs;Serotonin receptor;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals |
| Mol File: | 85650-52-8.mol |
Mirtazapine Chemical Properties
| Melting point | 114-116°C |
| Boiling point | 432.4±45.0 °C(Predicted) |
| density | 1.22±0.1 g/cm3(Predicted) |
| Fp | 9°C |
| storage temp. | 2-8°C |
| solubility | DMSO: ~8 mg/mL, soluble |
| pka | 8.10±0.20(Predicted) |
| form | solid |
| color | white |
| BCS Class | 1 |
| Major Application | pharmaceutical (small molecule) |
| InChI | InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3 |
| InChIKey | RONZAEMNMFQXRA-UHFFFAOYSA-N |
| SMILES | N12CCN(C)CC1C1=CC=CC=C1CC1=CC=CN=C21 |
| CAS DataBase Reference | 85650-52-8(CAS DataBase Reference) |
Safety Information
| Hazard Codes | Xn |
| Risk Statements | 22 |
| Safety Statements | 22-24/25 |
| RIDADR | UN1230 - class 3 - PG 2 - Methanol, solution |
| WGK Germany | 3 |
| RTECS | UQ4410250 |
| HS Code | 29339900 |
| Storage Class | 11 - Combustible Solids |
| Hazard Classifications | Acute Tox. 4 Oral STOT SE 3 |
| Chemical Properties | White Solid |
| Uses | Mirtazapine (Remeron, Avanza) is a potent tetracyclic antidepressant. Mirtazapine (Remeron, Avanza) used primarily in the treatment of depression. It is also sometimes used as a hypnotic, antiemetic, and appetite stimulant, and for the treatment of anxiet |
| Uses | Mirtazapine is an α2-Adrenergic blocker; analogue of Mianserin. Antidepressant. |
| Definition | ChEBI: Mirtazapine is a benzazepine and a tetracyclic antidepressant. It has a role as an alpha-adrenergic antagonist, a serotonergic antagonist, a histamine antagonist, an anxiolytic drug, a H1-receptor antagonist and a oneirogen. |
| Brand name | Remeron (Organon). |
| General Description | Mirtazapine is a tetracyclic antidepressant marketed under the trade names Remeron?, Avanza, or Zispin for treatment of depression.?This Certified Spiking Solution? is suitable for LC/MS or GC/MS applications in forensic analysis, clinical toxicology, or urine drug testing. |
| Biological Activity | Antidepressant agent; potent 5-HT 2 , 5-HT 3 and histamine H 1 receptor antagonist and moderately potent α 2 -adrenoceptor antagonist (pK i values are 8.05, ~ 8.1, 9.3 and 6.95 respectively). Enhances noradrenalin (NA) release in rat brain via inhibition of α 2 -adrenergic autoreceptors and displays only weak affinity for monoamine transporters (pK i values are 5.6, < 5 and < 5.1 for inhibition of NA, dopamine and 5-HT uptake respectively). Increases hippocampal NA and 5-HT levels in rats following systemic administration in vivo . |
| Biochem/physiol Actions | Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA). Mirtazapine agonizes selective adrenergic and serotonergic receptors so that both NE release and 5-HT1A mediated serotonergic signaling are increased. |
| Clinical Use | Antidepressant |
| Veterinary Drugs and Treatments | Currently, the only FDA approved indication for mirtazapine isdepression in humans. Reported veterinary uses include treatmentof chemotherapy-induced nausea and vomiting (CINV); anorexiaassociated with renal failure (azotemia), congestive heart failure,gastro-intestinal disorders, liver disease, or neoplasia. Other usessuggested include stress induced diseases; insomnia; post-pyometrasymptoms; and post-operative inappetance. Studies have shownthat mirtazapine also alleviated sleep apnea in rats and humans. There are case reports published in human literature of mirtazapineuse as treatment for non-mechanical vomiting after gastricbypass, CINV, obsessive-compulsive disorder, nocioceptionand chronic pain, migraine headache prophylaxis, anti-psychoticinduced akathisia, idiopathic nausea and vomiting, serotonin syndromeinduced nausea, anorexia, irritable bowel syndrome, resistanthyperemesis gravidarum, and for the treatment of negativesymptoms of schizophrenia. Studies in rats have also shown thatmirtazapine significantly improves memory. |
| Drug interactions | Potentially hazardous interactions with other drugs Alcohol: increased sedative effect. Antidepressants: possibly increased risk of serotonergic effects with fluoxetine, fluvoxamine or venlafaxine; CNS excitation and hypertension with MAOI and moclobemide - avoid. Antimalarials: avoid with artemether and lumefantrine and piperaquine with artenimol. Methylthioninium: risk of CNS toxicity - avoid if possible. |
| Metabolism | Extensively metabolised in the liver via CYP2D6, CYP1A2, and CYP3A4. The major biotransformation pathways are demethylation and oxidation followed by glucuronide conjugation. The N-desmethyl metabolite is pharmacologically active.Elimination is via urine and faeces (15%). |
| storage | Store at RT |
Mirtazapine Preparation Products And Raw materials
| Raw materials | 1-(3-Carboxypyrid-2-yl)-2-phenyl-4-methyl-piperazine-->1-(3-Cyanopyridyl-2)-2-Phenyl-4-Methylpyperazine-->1-Oxo Mirtazapine (Mirtazapine Impurity C)-->1-(3-Hydroxymethylpyridin-2-yl)-4-methyl-2-phenylpiperazine-->2-Amino-3-benzylpyridine-->2-Chloro-3-cyanopyridine-->Methanesulfonic acid-->1-Methyl-3-phenylpiperazine |
